Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy

Jérôme Favrod, Alexandra Nguyen, Caroline Fankhauser, Alban Ismailaj, Jean-David Hasler, Abel Ringuet, Shyhrete Rexhaj, Charles Bonsack, Jérôme Favrod, Alexandra Nguyen, Caroline Fankhauser, Alban Ismailaj, Jean-David Hasler, Abel Ringuet, Shyhrete Rexhaj, Charles Bonsack

Abstract

Background: Recent literature has distinguished the negative symptoms associated with a diminished capacity to experience (apathy, anhedonia) from symptoms associated with a limited capacity for expression (emotional blunting, alogia). The apathy-anhedonia syndrome tends to be associated with a poorer prognosis than the symptoms related to diminished expression. The efficacy of drug-based treatments and psychological interventions for these symptoms in schizophrenia remains limited. There is a clear clinical need for new treatments.

Methods: This pilot study tested the feasibility of a program to reduce anhedonia and apathy in schizophrenia and assessed its impact on 37 participants meeting the ICD-10 criteria for schizophrenia or schizoaffective disorders. Participants were pre- and post-tested using the Scale for the Assessment of Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia (CDSS). They took part in eight sessions of the Positive Emotions Program for Schizophrenia (PEPS)--an intervention that teaches participants skills to help overcome defeatist thinking and to increase the anticipation and maintenance of positive emotions.

Results: Thirty-one participants completed the program; those who dropped out did not differ from completers. Participation in the program was accompanied by statistically significant reductions in the total scores for Avolition-Apathy and Anhedonia-Asociality on the SANS, with moderate effect sizes. Furthermore, there was a statistically significant reduction of depression on the CDSS, with a large effect size. Emotional blunting and alogia remain stable during the intervention.

Discussion: Findings indicate that PEPS is both a feasible intervention and is associated with an apparently specific reduction of anhedonia and apathy. However, these findings are limited by the absence of control group and the fact that the rater was not blind to the treatment objectives.

Conclusions: PEPS is a promising intervention to improve anhedonia and apathy which need to be tested further in a controlled study.

Trial registration number: ISRCTN registry ISRCTN74048461, registered 18 may 2015.

Figures

Figure 1
Figure 1
CONSORT 2010 Flow Diagram

References

    1. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32(2):238–245. doi: 10.1093/schbul/sbj013.
    1. Hartmann MN, Hager OM, Reimann AV, Chumbley JR, Kirschner M, Seifritz E, Tobler PN, Kaiser S. Apathy but not diminished expression in schizophrenia is associated with discounting of monetary rewards by physical effort. Schizophr Bull. 2015;41(2):503–512. doi: 10.1093/schbul/sbu102.
    1. Ventura J, Wood RC, Hellemann GS. Symptom domains and neurocognitive functioning can help differentiate social cognitive processes in schizophrenia: a meta-analysis. Schizophr Bull. 2013;39(1):102–111. doi: 10.1093/schbul/sbr067.
    1. Tsang HW, Leung AY, Chung RC, Bell M, Cheung WM. Review on vocational predictors: a systematic review of predictors of vocational outcomes among individuals with schizophrenia: an update since 1998. Aust N Z J Psychiatry. 2010;44(6):495–504.
    1. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225–1237. doi: 10.1093/schbul/sbl071.
    1. Strauss GP, Horan WP, Kirkpatrick B, Fischer BA, Keller WR, Miski P, Buchanan RW, Green MF, Carpenter WT., Jr Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013;47(6):783–790. doi: 10.1016/j.jpsychires.2013.01.015.
    1. Turkington D, Morrison AP. Cognitive therapy for negative symptoms of schizophrenia. Arch Gen Psychiatry. 2012;69(2):119–120. doi: 10.1001/archgenpsychiatry.2011.141.
    1. Kendall T. Treating negative symptoms of schizophrenia, vol. 344. 2012.
    1. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2014;41:892–899. doi: 10.1093/schbul/sbu170.
    1. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry. 2007;164(3):428–436. doi: 10.1176/ajp.2007.164.3.428.
    1. Elis O, Caponigro JM, Kring AM. Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev. 2013;33(8):914–928. doi: 10.1016/j.cpr.2013.07.001.
    1. Granholm E, Holden J, Link PC, McQuaid JR, Jeste DV. Randomized controlled trial of cognitive behavioral social skills training for older consumers with schizophrenia: defeatist performance attitudes and functional outcome. Am J Geriatr Psychiatry. 2013;21(3):251–262. doi: 10.1016/j.jagp.2012.10.014.
    1. Couture SM, Blanchard JJ, Bennett ME. Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia. Psychiatry Res. 2011;189(1):43–48. doi: 10.1016/j.psychres.2011.05.032.
    1. Kring AM, Caponigro JM. Emotion in Schizophrenia: Where Feeling Meets Thinking. Curr Dir Psychol Sci. 2010;19(4):255–259. doi: 10.1177/0963721410377599.
    1. Buck B, Lysaker PH. Consummatory and anticipatory anhedonia in schizophrenia: stability, and associations with emotional distress and social function over six months. Psychiatry Res. 2013;205(1–2):30–35. doi: 10.1016/j.psychres.2012.09.008.
    1. Favrod J, Ernst F, Giuliani F, Bonsack C. Validation française de l'échelle d'expérience temporelle du plaisir. Encéphale. 2009;35(3):241–248. doi: 10.1016/j.encep.2008.02.013.
    1. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93(1–3):253–260. doi: 10.1016/j.schres.2007.03.008.
    1. Raffard S, Esposito F, Boulenger JP, Van der Linden M. Impaired ability to imagine future pleasant events is associated with apathy in schizophrenia. Psychiatry Res. 2013;209(3):393–400. doi: 10.1016/j.psychres.2013.04.016.
    1. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359–369. doi: 10.1093/schbul/sbn094.
    1. Strauss GP, Morra LF, Sullivan SK, Gold JM. The Role of Low Cognitive Effort and Negative Symptoms in Neuropsychological Impairment in Schizophrenia. Neuropsychology. 2014;29:281–291.
    1. Cassar R, Applegate E, Bentall RP. Poor savouring and low self-efficacy are predictors of anhedonia in patients with schizophrenia spectrum disorders. Psychiatry Res. 2013;210(3):830–834. doi: 10.1016/j.psychres.2013.09.017.
    1. Bryant FB. The Process of Savoring: A New Model of Positive Experience. Mahwah, NJ: Lawrence Erlbaum; 2007.
    1. Ursu S, Kring AM, Gard MG, Minzenberg MJ, Yoon JH, Ragland JD, Solomon M, Carter CS. Prefrontal cortical deficits and impaired cognition-emotion interactions in schizophrenia. Am J Psychiatry. 2011;168(3):276–285. doi: 10.1176/appi.ajp.2010.09081215.
    1. Kring AM, Germans Gard M, Gard DE. Emotion deficits in schizophrenia: timing matters. J Abnorm Psychol. 2011;120(1):79–87. doi: 10.1037/a0021402.
    1. Horan WP, Wynn JK, Kring AM, Simons RF, Green MF. Electrophysiological correlates of emotional responding in schizophrenia. J Abnorm Psychol. 2010;119(1):18–30. doi: 10.1037/a0017510.
    1. Quoidbach J, Berry EV, Hansenne M, Mikolajczak M. Positive emotion regulation and well-being: Comparing the impact of eight savoring and dampening strategies. Personality and Individual Differ. 2010;49(5):368–373. doi: 10.1016/j.paid.2010.03.048.
    1. Kring AM, Moran EK. Emotional response deficits in schizophrenia: insights from affective science. Schizophr Bull. 2008;34(5):819–834. doi: 10.1093/schbul/sbn071.
    1. Strauss GP. Translating basic emotion research into novel psychosocial interventions for anhedonia. Schizophr Bull. 2013;39(4):737–739. doi: 10.1093/schbul/sbt082.
    1. Moritz S, Veckenstedt R, Andreou C, Bohn F, Hottenrott B, Leighton L, Kother U, Woodward TS, Treszl A, Menon M, et al. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial. JAMA Psychiat. 2014;71(10):1103–1111. doi: 10.1001/jamapsychiatry.2014.1038.
    1. Turkington D, Sensky T, Scott J, Barnes TR, Nur U, Siddle R, Hammond K, Samarasekara N, Kingdon D. A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up. Schizophr Res. 2008;98(1–3):1–7. doi: 10.1016/j.schres.2007.09.026.
    1. Johnson DP, Penn DL, Fredrickson BL, Kring AM, Meyer PS, Catalino LI, Brantley M. A pilot study of loving-kindness meditation for the negative symptoms of schizophrenia. Schizophr Res. 2011;129(2–3):137–140. doi: 10.1016/j.schres.2011.02.015.
    1. Favrod J, Giuliani F, Ernst F, Bonsack C. Anticipatory pleasure skills training: a new intervention to reduce anhedonia in schizophrenia. Perspect Psychiatr Care. 2010;46(3):171–181. doi: 10.1111/j.1744-6163.2010.00255.x.
    1. Kring AM, Elis O. Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013;9:409–433. doi: 10.1146/annurev-clinpsy-050212-185538.
    1. Favrod J, Rexhaj S, Nguyen A, Cungi C, Bonsack C. Projecting Oneself into the Future, an Intervention for Improving Pleasure in Patients with Anhedonia. In: Ritsner MS, editor. Anhedonia: A Comprehensive Handbook Volume I: Conceptual Issues And Neurobiological Advances. Volume 1. Dordrecht: Springer Science+Business Media; 2014. pp. 95–104.
    1. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC. A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry. 2007;64(8):966–974. doi: 10.1001/archpsyc.64.8.966.
    1. Lecrubier Y, Boyer P. L'utilisation de la SANS et de la SAPS. Psychiatr Psychobiol. 1987;2:6.
    1. Dollfus S, Langlois S, Assouly-Besse F, Petit M. Depressive symptoms and negative symptoms during schizophrenia] Encéphale. 1995;21(Spec No 3):23–27.
    1. Lecrubier Y, Boyer P. Fiche descriptive et traduction française de la SANS. Psychiatrie & Psychobiologie. 1987;2:414–423.
    1. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;22:39–44.
    1. Reine G, Bernard D, Auquier P, Le Fur B, Lancon C. [Psychometric properties of French version of the Calgary depression scale for schizophrenics (CDSS)] Encéphale. 2000;26(1):52–61.
    1. Bryant FB. Savoring Beliefs Inventory (SBI): A scale for measuring beliefs about savouring. J Ment Health. 2003;12:175–196. doi: 10.1080/0963823031000103489.
    1. Rector NA, Beck AT, Stolar N. The negative symptoms of schizophrenia: a cognitive perspective. Can J Psychiat Rev canadienne de psychiatrie. 2005;50(5):247–257.
    1. Grant PM, Beck AT. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. Schizophr Bull. 2009;35(4):798–806. doi: 10.1093/schbul/sbn008.
    1. Kolb AY, Kolb DA. The Learning Way: Meta-cognitive Aspects of Experiential Learning. Simulation & Gaming. 2008;40(3):297–327. doi: 10.1177/1046878108325713.
    1. Borenstein M. Effect sizes for continuous data. In: Cooper H, Hedges LV, Valentine JC, editors. The handbook of research synthesis and meta analysis edn. New York: Russell Sage Foundation; 2009.
    1. Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord. 2015;180:179–184. doi: 10.1016/j.jad.2015.03.021.
    1. Schennach R, Obermeier M, Seemuller F, Jager M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, et al. Evaluating depressive symptoms in schizophrenia: a psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Psychopathology. 2012;45(5):276–285. doi: 10.1159/000336729.
    1. Villeneuve K, Potvin S, Lesage A, Nicole L. Meta-analysis of rates of drop-out from psychosocial treatment among persons with schizophrenia spectrum disorder. Schizophr Res. 2010;121(1–3):266–270. doi: 10.1016/j.schres.2010.04.003.
    1. Meyer PS, Johnson DP, Parks A, Iwanski C, Penn DL. Positive living: A pilot study of group positive psychotherapy for people with schizophrenia. J Positive Psychol. 2012;7:3. doi: 10.1080/17439760.2012.677467.
    1. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383–402. doi: 10.1093/schbul/sbn135.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi